VIBRANT

In Vivo Imaging of Beta cell Receptors by Applied Nano Technology

 Coordinatore Centrum fur Angewandte Nanotechnologie (CAN) GmbH 

 Organization address address: Grindelallee 117
city: Hamburg
postcode: 20146

contact info
Titolo: Dr.
Nome: Theo
Cognome: Schotten
Email: send email
Telefono: +49 40 42838 8214
Fax: +49 40 42838 5797

 Nazionalità Coordinatore Germany [DE]
 Sito del progetto http://www.fp7-vibrant.eu
 Totale costo 10˙563˙353 €
 EC contributo 8˙073˙000 €
 Programma FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies
 Code Call FP7-NMP-2008-LARGE-2
 Funding Scheme CP-IP
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-07-01   -   2013-06-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    Centrum fur Angewandte Nanotechnologie (CAN) GmbH

 Organization address address: Grindelallee 117
city: Hamburg
postcode: 20146

contact info
Titolo: Dr.
Nome: Theo
Cognome: Schotten
Email: send email
Telefono: +49 40 42838 8214
Fax: +49 40 42838 5797

DE (Hamburg) coordinator 1˙999˙686.00
2    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: Helena
Cognome: Nässén
Email: send email
Telefono: +468517 73122
Fax: +468517 76900

SE (STOCKHOLM) participant 1˙310˙794.00
3    UNIVERSITAET HAMBURG

 Organization address address: EDMUND-SIEMERS-ALLEE 1
city: HAMBURG
postcode: 20146

contact info
Titolo: Ms.
Nome: Linda
Cognome: Reams-Behboud
Email: send email
Telefono: +49 40 428384425
Fax: +49 40 428385627

DE (HAMBURG) participant 1˙067˙238.00
4    UMEA UNIVERSITET

 Organization address address: UNIVERSITETOMRADET
city: UMEA
postcode: 901 87

contact info
Titolo: Ms.
Nome: Tina
Cognome: Ledin
Email: send email
Telefono: 46907854437
Fax: 46907854400

SE (UMEA) participant 619˙574.00
5    UNIVERSITAET BREMEN

 Organization address address: Bibliothekstrasse 1
city: BREMEN
postcode: 28359

contact info
Titolo: Mr.
Nome: Sven
Cognome: Petersen
Email: send email
Telefono: 4942120000000
Fax: 4942120000000

DE (BREMEN) participant 611˙551.00
6    KATHOLIEKE UNIVERSITEIT LEUVEN

 Organization address address: Oude Markt 13
city: LEUVEN
postcode: 3000

contact info
Titolo: Ms.
Nome: Elke
Cognome: Lammertyn
Email: send email
Telefono: 3216329976
Fax: +32 16 326515

BE (LEUVEN) participant 609˙037.00
7    UNIVERSITAET BAYREUTH

 Organization address address: Universitaetsstrasse 30
city: BAYREUTH
postcode: 95447

contact info
Titolo: Mr.
Nome: Marcus
Cognome: Urban
Email: send email
Telefono: 49921555351
Fax: 4992160000000

DE (BAYREUTH) participant 533˙888.00
8    UNIVERSITE LIBRE DE BRUXELLES

 Organization address address: Avenue Franklin Roosevelt 50
city: BRUXELLES
postcode: 1050

contact info
Titolo: Prof.
Nome: Abdullah
Cognome: Sener
Email: send email
Telefono: 3225556240
Fax: 3225554219

BE (BRUXELLES) participant 494˙937.00
9    FUNDACIO CENTRE DE REGULACIO GENOMICA

 Organization address address: CARRER DOCTOR AIGUADER 88
city: BARCELONA
postcode: 8003

contact info
Titolo: Mr.
Nome: Stefan
Cognome: Pönisch
Email: send email
Telefono: 34393160264
Fax: 34933969983

ES (BARCELONA) participant 491˙005.00
10 KOBENHAVNS UNIVERSITET DK participant 273˙719.66
11    NOVO NORDISK A/S

 Organization address address: NOVO ALLE 1
city: BAGSVAERD
postcode: 2880

contact info
Titolo: Mr.
Nome: Toby Alexander
Cognome: Brunt
Email: send email
Telefono: 4544430623
Fax: 4544438000

DK (BAGSVAERD) participant 61˙570.34

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

offer    vivo    nanocontainers    cardiovascular    lower    diseases    mass    therapies    cell    health    people    limb    fatal    vibrant    mri    direct    blindness    care    amputation    beta    diabetes    prevalence    million    kidney   

 Obiettivo del progetto (Objective)

'Currently, around 30 million people in the enlarged Europe suffer from diabetes, with a prevalence of 7.5% in member states. In recent years the emergence of type 2 diabetes in children and adolescents is a new and serious health challenge to the youth of Europe, their families and society. By 2025, the number of people with diabetes is expected to rise to around 50 million in Europe, thus increasing prevalence to 10.9%. This devastating disease is ranked among the leading causes of fatal cardiovascular diseases, kidney failure, neuropathy, lower limb amputation and blindness. Estimates of annual direct cost of diabetes care in Europe are currently EUR 50 billion. The indirect costs of diabetes i.e. the cost of lost production are as high as direct costs or even higher. Diabetes results from an absolute or relative decline in pancreatic β-cell function and/or mass. Although of ultimate importance for diabetes management and the development of new therapies, hitherto, no clinically established methodology for non-invasive in vivo imaging and quantification of β-cell mass (BCM) exists. VIBRANT proposes superparamagnetic fluorous phase nanocontainers (FPNC), which are functionalized with β-cell specific ligands for in vivo MRI. This combines β-cell specific targeting with the unrivalled MRI sensitivity of supermagnetic particles and the high resolution power of 19F-containing contrast agents, and hence will outperform existing MRI technology. Furthermore, target specific drug-loaded nanocontainers will offer high potential for β-cell directed therapies. VIBRANT will offer theranostic solutions to the utmost urgent problems in the health care management of diabetes, substantially improving the early diagnosis, thus preventing distressful and costly complications, contributing to the development of new therapies for the regeneration of β-cell mass, and thus directly impacting health status and life quality of patients, health care budgets and economies within the EU.'

Introduzione (Teaser)

Diabetes prevalence in Europe is reaching epidemic proportions and the millions of suffers are estimated to double by 2025. If not promptly treated, diabetes can lead to fatal cardiovascular diseases, kidney failure, lower limb amputation and blindness.

Altri progetti dello stesso programma (FP7-NMP)

WAFERLEVELOPTICS (2010)

WaferLevelOptics - Specific Technological Developments to Create an Intelligent and Scalable Production Platform for Glass Optics Manufacturing

Read More  

EUROTAPES (2012)

European development of Superconducting Tapes: integrating novel materials and architectures into cost effective processes for power applications and magnets

Read More  

NEURONANO (2009)

Do nanoparticles induce neurodegenerative diseases? Understanding the origin of reactive oxidative species and protein aggregation and mis-folding phenomena in the presence of nanoparticles

Read More